FDA Grants Broadened Indication for Afatinib in First-Line Treatment of Certain Patients with Metastatic NSCLC

On Jan. 12, 2018, the U.S. Food and Drug Administration (FDA) granted approval to afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

Read the FDA announcement.

Posted 1/12/2018